A Comparison of Treatment Methods for the Prophylaxis of Recurrent Superficial Bladder Tumors
- 1 January 1983
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 129 (1) , 33-34
- https://doi.org/10.1016/s0022-5347(17)51905-9
Abstract
Fifty-five patients with superficial transitional cell carcinoma of the bladder were assigned by rotation to 1 of 3 treatment categories. Group 1 patients were treated by transurethral resection alone, group 2 by transurethral resection followed by topical thiotepa and group 3 by transurethral resection followed by orally administered BCG. Recurrent bladder tumors developed subsequently in 80% of the patients in group 1, 42.9% in group 2 and 6.2% in group 3.This publication has 10 references indexed in Scilit:
- Treatment of disseminated malignant melanoma with high-dose oral BCGCancer, 1981
- Nonspecific Immunotherapy with BCG Vaccine in Bladder TumorsEuropean Urology, 1977
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976
- The Prophylactic Use of Thio-Tepa and Urokinase in Transitional Cell Carcinoma of the Bladder: A Preliminary ReportJournal of Urology, 1975
- Current and Future Concepts of Lung CancerAnnals of Internal Medicine, 1975
- BCG and CancerNew England Journal of Medicine, 1974
- Evaluation of Immunological Reactivity in Bladder CancerBritish Journal of Urology, 1974
- Chemotherapy for bladder cancerUrology, 1974
- Correlation Among Host Immunocompetence and Tumor Stage, Tumor Grade and Vascular Permeation in Transitional CarcinomaJournal of Urology, 1973
- Immunological Factors in Human Sarcomas and MelanomasAnnals of Surgery, 1970